NI200700299A - Composicion de liberación modificada de al menos una forma de venlafaxina - Google Patents

Composicion de liberación modificada de al menos una forma de venlafaxina

Info

Publication number
NI200700299A
NI200700299A NI200700299A NI200700299A NI200700299A NI 200700299 A NI200700299 A NI 200700299A NI 200700299 A NI200700299 A NI 200700299A NI 200700299 A NI200700299 A NI 200700299A NI 200700299 A NI200700299 A NI 200700299A
Authority
NI
Nicaragua
Prior art keywords
venlafaxine
composition
modified release
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NI200700299A
Other languages
English (en)
Inventor
Fang Zhou
Werner Oberegger
Paul Maes
Original Assignee
Biovail Lab Internac Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovail Lab Internac Srl filed Critical Biovail Lab Internac Srl
Publication of NI200700299A publication Critical patent/NI200700299A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición de liberación modificada de al menos una forma de venlafaxina, que es una composición de liberación controlada retardada. La composición comprende un núcleo que contiene al menos una forma de venlafaxina seleccionada del grupo que consiste en velafaxina, un metabolito activo de venlafaxina, una sal farmacéuticamente aceptable de venlafaxina, una sal farmacéuticamente aceptable de un metabolito activo de venlafaxina y sus combinaciones, menos de 10% de un gelificante y un excipiente farmacéuticamente aceptable. La composición comprende además un recubrimiento de liberación modificada que prácticamente rodea el núcleo que proporciona una liberación controlada retardada de la al menos una forma de venlafaxina.-
NI200700299A 2005-06-02 2007-11-19 Composicion de liberación modificada de al menos una forma de venlafaxina NI200700299A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68646105P 2005-06-02 2005-06-02
US69128205P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
NI200700299A true NI200700299A (es) 2008-07-24

Family

ID=37492005

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700299A NI200700299A (es) 2005-06-02 2007-11-19 Composicion de liberación modificada de al menos una forma de venlafaxina

Country Status (11)

Country Link
US (2) US20070098797A1 (es)
EP (1) EP1885340A1 (es)
JP (1) JP2008542394A (es)
KR (1) KR20080013927A (es)
AU (1) AU2006252394A1 (es)
CR (1) CR9555A (es)
IL (1) IL186756A0 (es)
MX (1) MX2007014963A (es)
NI (1) NI200700299A (es)
RU (1) RU2007143087A (es)
WO (1) WO2006130843A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007143087A (ru) * 2005-06-02 2009-07-20 Биовэйл Лэборэториз Интернэшнл С.Р.Л. (Bb) Композиция с модифицированным высвобождением минимум одной формы венлафаксина
US20080175873A1 (en) * 2005-06-02 2008-07-24 Biovail Laboratories International S.R.L. Modified release composition of at least one form of venlafaxine
WO2007112574A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Extended release composition of venlafaxine
KR100965527B1 (ko) * 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
US20110052690A1 (en) * 2008-06-02 2011-03-03 Avi Avramoff Process for manufacture of a medicament with granulation and pan coating
TW201113266A (en) * 2009-09-02 2011-04-16 Ziopharm Oncology Inc Pharmaceutical formulations for indibulin
EP2668945A1 (de) * 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US432607A (en) * 1890-07-22 dwyer
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US20050244498A1 (en) * 2001-09-14 2005-11-03 Biovail Laboratories, Inc. Modified-release compositions of at least one form of venlafaxine
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
US20030133982A1 (en) * 2001-12-20 2003-07-17 Heimlich John M. Zero-order sustained release dosage forms and method of making same
US6717015B2 (en) * 2002-03-28 2004-04-06 Synthon Bv Venlafaxine besylate
RU2007143087A (ru) * 2005-06-02 2009-07-20 Биовэйл Лэборэториз Интернэшнл С.Р.Л. (Bb) Композиция с модифицированным высвобождением минимум одной формы венлафаксина
US20080175873A1 (en) * 2005-06-02 2008-07-24 Biovail Laboratories International S.R.L. Modified release composition of at least one form of venlafaxine

Also Published As

Publication number Publication date
RU2007143087A (ru) 2009-07-20
WO2006130843A1 (en) 2006-12-07
JP2008542394A (ja) 2008-11-27
US20090269402A1 (en) 2009-10-29
KR20080013927A (ko) 2008-02-13
MX2007014963A (es) 2008-04-17
EP1885340A1 (en) 2008-02-13
CR9555A (es) 2008-06-12
US20070098797A1 (en) 2007-05-03
AU2006252394A1 (en) 2006-12-07
IL186756A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
NI200700299A (es) Composicion de liberación modificada de al menos una forma de venlafaxina
AR061289A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
AR050717A1 (es) Composiciones farmaceuticas
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
PE20210668A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
HN2010002121A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
CL2011001853A1 (es) Uso de una combinacion farmaceutica que comprende linagliptina y un segundo agente antidiabetico seleccionado entre biguanidas, tiazolidindionas, sulfonilureas, glinidas, entre otros, y, opcionalmente, un tercer agente antidiabetico, para tratar diabetes mellitus tipo 2 y complicaciones de la diabetes, entre otras.
CR9354A (es) Productos de microcapsula de liberacion rapida
AR086652A1 (es) Metodos de tratamiento, composiciones farmaceuticas y usos de los mismos
PE20090951A1 (es) Suspension pediatrica estabilizada de carisbamato
UY33665A (es) Derivado peptídico
EA201071166A1 (ru) Контролируемое высвобождение активных агентов из олеосом
CR11864A (es) Preparación de formas farmacéuticas relajantes de músculos esqueléticos de liberación controlada
DOP2008000053A (es) Inhibidores de akt(proteinas cinasa b)
AR039936A1 (es) Formulacion farmaceutica de liberacion modificada
CR20110209A (es) Composición farmacéutica sólida
AR075308A1 (es) Composicion para controlar fitoenfermedades y metodo para controlar fitoenfermedades
WO2009014105A1 (ja) 新規カルボン酸およびそれを有効成分とする抗うつ用組成物
AR065342A1 (es) Composiciones farmaceuticas que contienen fumarato de quetiapina
BRPI0410044A (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
ES2582660T3 (es) Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina
AR061165A1 (es) Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas
DOP2006000030A (es) Nueva forma de sal de un agonista de dopamina
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.